Objective: Obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) are heritable neurodevelopmental disorders with a partially shared genetic etiology. This study represents the first genome-wide investigation of large (>500 kb), rare (<1%) copy number variants (CNVs) in OCD and the largest genome-wide CNV analysis in TS to date. Method: The primary analyses used a cross-disorder design for 2,699 case patients (1,613 ascertained for OCD, 1,086 ascertained for TS) and 1,789 controls. Parental data facilitated a de novo analysis in 348 OCD trios. Results: Although no global CNV burden was detected in the cross-disorder analysis or in secondary, disease-specific analyses, there was a 3.3-fold increased burden of large deletions previously associated with other neurodevelopmental disorders (p = .09). Half

Supplemental material cited in this article is available online.
of these neurodevelopmental deletions were located in a single locus, 16p13.11 (5 case patient deletions: 0 control deletions, \( p = .08 \) in the current study, \( p = .025 \) compared to published controls). Three 16p13.11 deletions were confirmed de novo, providing further support for the etiological significance of this region. The overall OCD de novo rate was 1.4%, which is intermediate between published rates in controls (0.7%) and in individuals with autism or schizophrenia (2-4%). Conclusion: Several converging lines of evidence implicate 16p13.11 deletions in OCD, with weaker evidence for a role in TS. The trend toward increased overall neurodevelopmental CNV burden in TS and OCD suggests that deletions previously associated with other neurodevelopmental disorders may also contribute to these phenotypes. J. Am. Acad. Child Adolesc. Psychiatry, 2014;53(8):910–919. Key Words: Tourette syndrome, obsessive-compulsive disorder, copy number variation, genetics, 16p13.11

Obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) are neurodevelopmental disorders with significant phenotypic and genetic overlap. One promising avenue for identifying cross-disorder genetic risk factors in neurodevelopmental disorders is the study of genomic copy number variants (CNVs), segments of DNA ranging from 1 kilobase to several megabases that show deletions or duplications compared to a reference. The association of large rare CNVs with neurodevelopmental disorders including autism spectrum disorders (ASD), schizophrenia, and intellectual disability (ID) has been one of the most important recent advances in psychiatric genomics. CNVs predisposing individuals to these disorders overlap substantially, highlighting the cross-disorder effects of this class of genetic variation. Given this robust literature, an important, unanswered question is whether large rare CNVs are also relevant for the genetic architecture of OCD and TS.

Both OCD and TS are highly heritable and have long been suspected to share genetic liability, although specific gene variants have been difficult to identify. Both disorders frequently co-occur in individuals, and there is evidence for shared OCD/TS genetic risk from family studies, with genetic correlation estimates ranging from 41% to 90%. In OCD, locus-specific CNV analyses have been reported, but no prior genome-wide CNV analysis has been performed. In TS, the 3 previous genome-wide surveys of CNVs have been limited by small sample sizes (<500 patients), and results differ with regard to whether there is an increased CNV burden in individuals with TS compared to controls. No specific CNV region has received strong statistical support across studies, although exonic \( NRXN1 \) deletions have been identified in 2 studies.

Given the evidence for shared genetic underpinnings of OCD and TS and cross-disorder effects of specific neurodevelopmental CNVs, along with the need for large samples when investigating rare events, we chose a cross-disorder design that combined OCD and TS samples into a single case group, with follow-up analyses examining the individual disorders. This study is the first genome-wide CNV analysis in OCD and the largest to date in TS and addressed 3 key questions. First, is there an increased burden of large rare CNVs in OCD/TS? Second, are the recurrent and/or de novo CNVs implicated in other neurodevelopmental disorders also etiologically relevant for OCD/TS? Third, is there evidence of association between any specific genomic region and OCD/TS?

**METHOD**

**Participants**

Individuals with OCD or TS were recruited for a multicenter collaborative genome-wide association study (genome-wide association study [GWAS]; described by Scharf et al. and Stewart et al.). Participants aged 18 years and older provided written, voluntary informed consent for participation in genetic studies. Individuals aged less than 18 years provided assent; parents provided written consent. The study was approved by the Ethics Committees of all participating sites. Recruitment sites varied in screening and exclusions related to other neurodevelopmental disorders (see supplementary Tables S9, S10, and S11, available online, for available clinical information regarding ID, ASD, attention-deficit/hyperactivity disorder [ADHD], and seizures). OCD and TS samples were collected independently but were genotyped jointly to facilitate cross-disorder analyses. All patients were genotyped on the Illumina Human610-Quadv1_B platform.

**OCD.** The initial OCD sample consisted of 1,565 case patients and 437 parent–child trios (\( n = 406 \) independent families, 31 affected siblings) recruited from 22 sites in the United States, Canada, Europe, Latin America,
and South Africa, predominantly through OCD specialty clinics. In total, 1,971 independent case patients with OCD (including trio probands) were eligible for analysis. A total of 1,613 case patients with OCD (82%) survived quality control (QC), and were included in the final analyses. Mean age of OCD symptom onset was 13.8 years (SD = 9.1). In all, 327 patients and 21 affected siblings had parents available for de novo analysis (n = 348 total trios). TS or chronic tics (CT) were assessed in 57% of OCD probands using 348 total trios). TS or chronic tics (CT) were assessed in 88% of patients; OCD as defined by DSM-IV-TR criteria was assessed in 88% of patients; OCD was present in 46% of assessed TS individuals.

Controls. Ancestry-matched controls (n = 720) were collected in parallel with their respective patients for the French-Canadian (n = 269), German (n = 224), South African (n = 188), and Dutch (n = 39) samples. These controls were screened for TS and OCD and genotyped with patients on the Illumina Hu- man610-Quadv1_B20,21 (referred to here as “Hap610 controls”).

A total of 1,279 additional European-ancestry controls were obtained through the Database of Genotypes and Phenotypes (dbGaP) from the Studies of Addiction: Genetics and Environment (SAGE) cohort.20 SAGE controls were excluded for lifetime substance dependence but were not screened for other psychopathology. The SAGE controls were genotyped on the Illumina Human-Hap1Mv1_C (referred to here as “Hap1M controls”).

CNV Calling and Quality Control
Data from the Hap610 (case patients and controls) and Hap1M (controls) platforms were processed and cleaned separately using standard procedures (see Supplementary Materials, available online). CNV calls were generated with PennCNV (version 2010-05-01)22 and iPattern22,23 using hg18 genomic coordinates. Analyses were limited to autosomal events. Tri-o analyses used the trio functions in PennCNV to improve calling accuracy and to estimate the likelihood of a de novo event.21

Both sample and CNV-specific QC was conducted by examining distributions of QC metrics informed by comparable published CNV analyses.22,24,25 Because distributions were similar for calls from PennCNV and iPattern, the same QC thresholds were used for both algorithms to maximize comparability (see Supplementary Materials, available online). QC-filtered PennCNV and iPattern callsets were merged at the sample level using CNVision (http://futo.cs.yale.edu/mw/index.php/CNVision). Only calls with >50% overlap based on the union of the CNV region were included in the analysis. Overlap percentages were higher for the Hap1M (86%–98%) compared to the Hap610 chip (59%–82%; Table S1, available online). Because of the presence of a batch effect within the Hap610 samples, analyses were restricted to large (>500-kb) events, the size at which batch effects were no longer observed (Figure S1, Table S2, available online). All CNVs were also filtered for rare events (<1% frequency in the Database of Genomic Variants).

RESULTS
After filtering and QC, the final sample consisted of 2,699 case patients (1,086 ascertained for TS and 1,613 ascertainment for OCD) and 1,789 controls.

Overall CNV Burden Analysis
There was no significant difference in burden of large rare CNVs between case patients with

Ancestry Matching
The case patient-control sample was predominantly composed of individuals self-reporting European (EU) ancestry (n = 4,410), but did include a small number of individuals from Brazil, Mexico, and Costa Rica (n = 78) to maximize the power to detect rare events. However, a sensitivity analysis restricted to genetically defined EU ancestry (n = 4,276) via multidimensional scaling (Figures S2, S3, available online) confirmed that results were not biased by population stratification.
OCD/TS and controls for CNV rate (average number of CNVs per person), CNV proportion (proportion of samples carrying \(\geq 1\) CNV), gene rate (average number of genes spanned by a CNV), or by restricting to CNVs containing exons (Tables 1, S4, S5, S6; Tables S4–S6 are available online). Similarly, no increased CNV burden was identified in secondary, disorder-specific analyses (OCD versus controls or TS versus controls; Tables S7, S8, available online).

Neurodevelopmental CNV Burden Analysis

Given that various neurodevelopmental disorders have previously been associated with large, rare, recurrent CNVs in specific regions of the genome,4 we examined known pathogenic neurodevelopmental loci for an excess of large rare CNVs in OCD/TS patients compared to controls (Tables 2, 3, S3, S9; Tables S3 and S9 are available online). We found a 3.3-fold trend-level increase in large deletions overlapping these loci for case patients with TS/OCD (\(p = .09\); Table 2). In contrast, there was no enrichment of duplication events (case/control ratio 1.16, \(p = .46\)) and no difference in overall CNV size within these regions (\(p = .31\)).

In disorder-specific analyses, the neurodevelopmental deletion burden was larger in OCD (case/control ratio = 4.44, \(p = .04\), 1-sided) than in TS (case/control ratio = 1.65, \(p = .49\), 1-sided) (Tables S7, S8, available online). The most frequently observed neurodevelopmental CNVs were located at 16p13.11, 22q11, and PARK2 (Figure 1, Tables 3, S4, S5; Tables S4, S5 are available online).

Laboratory Validation

We confirmed 10 of 11 neurodevelopmental deletion events (91%) with qPCR; the 1 unconfirmed deletion was near the 9q34 telomere and was excluded from the neurodevelopmental burden analysis (see Supplementary Materials, available online). We also confirmed 12 of 14 duplication events (86%) with 1 or 2 sets of primers. The 2 remaining duplications could not be confirmed but had qPCR results trending toward duplication. Of note, the LRR and BAF plots (Figure S6, available online) strongly supported all CNV events with the exception of the unconfirmed 9q34 deletion.

Region-specific Analyses

Half of the 10 large neurodevelopmental deletions were in the same genomic region on 16p13.11 (case:control ratio = 5.0, 1-sided Fisher’s exact \(p = .08\)) (Figure 1, Table 3). Using previously published estimates to more accurately calculate the control rate for 16p13.11 deletions (3/8,329),28 we found a statistically significant excess in the OCD/TS patients (1-sided Fisher’s exact \(p = .025\)). Of note, the rate of 16p13.11 deletions in this sample (0.19%) was comparable to published rates from large samples of children with neurodevelopmental disorders (n = ~15,000) referred for genetic testing (0.11%–0.14%).28,29 Interestingly, the clinical phenotype of the 5 cases with 16p13.11 deletions did not respect traditional diagnostic boundaries: 3 case patients had OCD without tics, 1 had TS without OCD, and 1 had OCD+CT.

TABLE 1 Global Burden Analysis of Large (>500 kb), Rare (<1%) Copy Number Variants (CNVs) in Patients Ascertained for Obsessive-Compulsive Disorder (OCD) or Tourette Syndrome (TS) Compared to Controls

<table>
<thead>
<tr>
<th>Description</th>
<th>Combined OCD/TS (n = 2,699)</th>
<th>Hap610 Controls (n = 561)</th>
<th>Hap1M Controls (n = 1,228)</th>
<th>Case/Control Ratio</th>
<th>(p) Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>All CNVs</td>
<td>No. of CNVs</td>
<td>186</td>
<td>39</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>&gt; 500 kb</td>
<td>Rate</td>
<td>0.069</td>
<td>0.070</td>
<td>0.090</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>Proportion</td>
<td>0.067</td>
<td>0.068</td>
<td>0.086</td>
<td>0.84</td>
</tr>
<tr>
<td></td>
<td>Gene rate</td>
<td>7.23</td>
<td>5.16</td>
<td>6.25</td>
<td>1.21</td>
</tr>
<tr>
<td>Deletions</td>
<td>No. of CNVs</td>
<td>60</td>
<td>7</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>&gt; 500 kb</td>
<td>Rate</td>
<td>0.022</td>
<td>0.012</td>
<td>0.025</td>
<td>1.05</td>
</tr>
<tr>
<td></td>
<td>Proportion</td>
<td>0.022</td>
<td>0.012</td>
<td>0.025</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>Gene rate</td>
<td>6.29</td>
<td>4.00</td>
<td>4.39</td>
<td>1.46</td>
</tr>
<tr>
<td>Duplications</td>
<td>No. of CNVs</td>
<td>126</td>
<td>32</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>&gt; 500 kb</td>
<td>Rate</td>
<td>0.047</td>
<td>0.057</td>
<td>0.065</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Proportion</td>
<td>0.046</td>
<td>0.055</td>
<td>0.063</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Gene rate</td>
<td>7.63</td>
<td>5.42</td>
<td>6.75</td>
<td>1.20</td>
</tr>
</tbody>
</table>

Note: gene rate = average number genes spanned by CNVs; proportion = proportion of samples with \(\geq 1\) CNV; rate = average number of CNVs per person.

*One-sided, empirical \(p\) value.
None of the case patients had ASD, ID, or a seizure disorder (Table S10, available online). All 16p13.11 deletions were validated with qPCR.

16p13.11 was also the top recurrent region in genome-wide, region-specific analyses combining deletions and duplications (case:control ratio = 7:1, 1-sided empirical $p = .13$; genome-wide permutation-corrected $p = .86$). This region-specific effect was driven by deletions; no excess of 16p13.11 duplications was found in case patients with OCD/TS compared either to sample controls (case:control ratio = 2:1, 1-sided Fisher’s exact $p = .65$) or to published controls (10/8,329)$^{28}$ (1-sided Fisher’s exact $p = .83$).

We also examined genome-wide, region-specific associations in each disorder separately, combining deletions and duplications. In OCD, 16p13.11 again emerged as the locus with the most notable case:control excess (6:1; 1-sided empirical $p = .046$, genome-wide permutation-corrected $p = .35$). In TS, the 3p26.3 region had the largest case:control excess (7:2 ratio of duplications 50 kb upstream of CNTN6; 1-sided empirical $p = .018$, genome-wide permutation-corrected $p = .15$); exonic CNTN6 regions had a more equivocal case:control ratio (8:6; 1-sided empirical $p = .11$, genome-wide permutation-corrected $p = .99$; see Figure S7, available online).

De Novo Analyses
The OCD parent–proband trios (total trios = 348) were examined for the presence of large (>500-kb), rare, de novo CNVs. We detected 5 high-confidence de novo CNVs at 4q24, 7p21.1-7p21.2, 16p13.11, 17q12, and 22q11.21, resulting in a de novo rate of 1.44% (Figure S8, available online). Three of these CNVs were in known pathogenic neurodevelopmental loci: 16p13.11, 17q12, 22q11.21 (Table S3, available online). All 5 events were validated in silico and by qPCR (Table S11, available online).

Given that 16p13.11 contained both a de novo CNV and the largest case patient/control difference across the genome, we undertook further investigation of the de novo status of other 16p13.11 case patient CNVs in our sample. Parental DNA was available for 1 of the 5 16p13.11 deletions (TS only), which we confirmed as de novo using qPCR. We also re-examined trios removed during QC for evidence of large 16p13.11 events, and found 1 additional deletion (OCD only) with a statistically significant in silico probability of being de novo ($p = 5.68 \times 10^{-14}$ that we subsequently validated using qPCR (Figure S8, available online). This increased the total number of 16p13.11 deletions from 5 to 6, 3 of which were de novo (2 OCD only, 1 TS only; see Table S10, available online). The de novo status of 2 16p13.11 deletions could not be determined because parental DNA was not available; 1 deletion was inherited.

### DISCUSSION

In this GWAS of large rare CNVs in OCD and TS, although there was no global increase in CNV burden, we did find suggestive evidence for an increased burden of known pathogenic neurodevelopmental deletions in case patients with OCD/TS compared to controls. The 3.3-fold increased risk associated with this finding reached only trend-level significance, potentially due to the conservative bias toward the null introduced by having the majority of controls genotyped on a more sensitive, higher-density genotyping array than case patients.

Deletions at 16p13.11, which contributed disproportionately to the neurodevelopmental burden, have been implicated in a wide range of disorders, including ID/developmental delay$^{28,29}$, seizures$^{30,31}$, and, less strongly, ASD$^{32}$.
confirmation of 3 de novo events among our 6 case
patients with OCD/TS 16p13.11 deletions, as well
as the absence of comorbid ID, seizures, or ASD in
the case patients assessed, suggests that these
events may be pathogenic in our sample and that
the phenotypic spectrum of 16p13.11 deletions
should be expanded to include OCD and TS.
Importantly, the phenotypic profiles indicate that
16p13.11 deletions are primarily associated with
OCD (4 OCD only, 1 OCD + CT, 1 TS only). The
presence of a case patient with TS but without OCD
raises the possibility of a pleiotropic effect of this
locus, although this hypothesis remains pre-
liminary, as it is based only on a single case patient.
It is also likely that additional genetic and envi-
ronmental factors shape the ultimate phenotypic
outcome of these CNV events, including patterns of
comorbidity.

Three of the 5 large de novo CNVs reported in
this study were located in regions previously
associated with other neurodevelopmental dis-
orders. The de novo events at 16p13.11 and 22q11
also had additional supporting case patient
events in the same locus, whereas the deletion at
17q12 was a singleton event in a case patient with
OCD. The final 2 de novo events were singleton
The clinical significance of both events remains
unclear, although pathogenic CNVs have
been documented in both regions (www.
iscaconsortium.org),33 including a report of a patient with Saethre-Chotzen syndrome and co-
occurring TS and OCD.34

The overall de novo rate in the OCD trio sample
was 1.44% for large CNVs (>500 kb), which is in-
termediate between estimates in healthy controls
(0.7%)27 and estimates in ASD (1.8% multiplex,
3.9% simplex)27 and schizophrenia (2%–3%).35-37
Additional studies with larger samples and more
sensitive CNV calling will be needed to refine this
estimate.

Previous CNV studies have implicated NRXN1
deletions in TS.15,17 We detected one 600-kb
NRXN1 deletion in a case patient with OCD (TS
status unknown) (chr2:50185814–50799877, hg18)
that was called by iPattern and qPCR-validated,
although it did not pass initial QC because <50%
of the region was called by PennCNV. We also
observed three 22q11 duplications, all case patients
with OCD (2 OCD only, 1 OCD+CT, 1 TS only).
The de novo 22q11 deletion was smaller (~700 kb)
than the canonical 1.5 to 3-Mb 22q11 deletion associated
with velocardiofacial and DiGeorge syndrome
(OMIM 192430, 188400), whereas the duplications
ranged in size from 700 kb to 2MB. Although the
3:1 22q11 CNV duplication excess in our sample is
not significant, it is notable that 3 other 22q11 dupli-
cations, including 1 de novo event, have

### Table 3: Large Rare Copy Number Variants (CNVs) in Case Patients and Controls Overlapping Previously Identified Neurodevelopmental Loci

<table>
<thead>
<tr>
<th>Chr</th>
<th>Region</th>
<th>Deletions</th>
<th>Duplications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Case Patients (OCD Only/TS Only/OCD+TS/CT), n = 2,699</td>
<td>Controls, n = 1,789</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case Patients (OCD Only/TS Only/OCD+TS/CT), n = 2,699</td>
<td>Controls, n = 1,789</td>
</tr>
<tr>
<td>2</td>
<td>2p15–16.1</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>2</td>
<td>2q11.2</td>
<td>0 0 0</td>
<td>0 0 0</td>
</tr>
<tr>
<td>3</td>
<td>CNTN4</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>3</td>
<td>3q29</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>6</td>
<td>PARK2</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>7</td>
<td>7q11.23</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>12</td>
<td>12q14</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>15</td>
<td>15q11–q13</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>15</td>
<td>15q24</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>16</td>
<td>16p13.11</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>16</td>
<td>16p11.2</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>17</td>
<td>NF1</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>17</td>
<td>17q12</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
<tr>
<td>22</td>
<td>22q11.21</td>
<td>0 0 0</td>
<td>0 1 1.00</td>
</tr>
</tbody>
</table>

Note: Chr = chromosome; CT = chronic tics; OCD = obsessive-compulsive disorder; TS = Tourette syndrome.

aFisher’s exact 1-sided p value.
previously been reported in TS patients,\textsuperscript{16,17,38,39} and thus this region warrants further study.

The results of this study should be interpreted in the context of some limitations. First, the majority of controls were genotyped on a higher-resolution array (Hap1M) than were case patients (Hap610), resulting in a conservative bias toward the null hypothesis because of better CNV detection in controls than in case patients. This effect is evident when comparing the higher CNV rates in Hap610 controls to Hap1M controls (Table 1). However, a comparison of Hap610 patients to Hap610 controls did not reveal overall burden differences within the limits of this restricted sample size (Table S12, available online).

Second, we were unable to call CNVs smaller than 500 kb because of genotyping batch effects. Although previous research has shown that >500 kb events are most likely to be pathogenic,\textsuperscript{22,25} we may have missed smaller pathogenic CNVs in this sample. Third, although it is the largest for OCD and TS to date, our sample is still small compared to large-scale investigations of CNVs in other disorders.\textsuperscript{4,28,29} For this reason, and because the number of case patients with OCD/TS and rare pathogenic CNVs appears to be small, we recommend caution in interpreting these results, pending further studies in larger OCD/TS samples that can refine the global and neurodevelopmental CNV burden estimates.

Fourth, missing data on TS/CT and OCD co-morbidity in some individuals prevented us from dividing case patients into mutually exclusive subgroups (TS only, OCD only, OCD+TS) for analysis. Instead, we identified CNVs in the combined OCD/TS sample and then reviewed the diagnostic profile of each research participant with a CNV. Moreover, TS and OCD participants were not universally screened for other neurodevelopmental disorders, although we documented this information when available (Tables S9, S10, S11, available online). Without comprehensive screening, we cannot exclude 2 possibilities regarding patients with neurodevelopmental CNVs: first, the primary TS/OCD diagnosis was misclassified (i.e., stereotypies or restricted interests/repetitive behaviors in the context of ASD were misdiagnosed as TS or OCD, respectively); and second, patients with complex comorbidities were more likely to harbor neurodevelopmental CNVs. All assessments were completed by internationally recognized expert clinicians, reducing the likelihood of

\textbf{FIGURE 1} 16p13.11 Region with 8 case patient and 1 control copy number variants (CNVs). Note: red denotes deletions; blue, duplications. Gray denotes the de novo deletion that did not survive strict quality control filters but was validated in silico and by quantitative polymerase chain reaction.
misclassification. However, some individuals with neurodevelopmental CNVs may have had subtle or unassessed ASD, ADHD, cognitive impairment, or psychotic symptoms.

These results suggest that deletions associated with other neurodevelopmental disorders may also contribute to OCD and TS. Converging lines of evidence specifically implicate 16p13.11 deletions, with stronger evidence for OCD than TS. Although it is premature to make clinical recommendations based on these observations, we note that tic and obsessive-compulsive symptoms often occur in the context of other neurodevelopmental disorders, such as ASD and ID, where practice parameters do recommend chromosomal microarray testing.40 Future studies should help to refine clinical guidelines as to whether CNV testing might be indicated for children with TS and/or OCD in general or should be restricted to those with multiple co-occurring neurodevelopmental disorders. 

Accepted June 18, 2014.

This article was reviewed under and accepted by ad hoc editor Robert R. Allsop, MD, PhD.

Dr. McGrath, Illmann, Fagerness, Geller, Jenike, Neale, Petershyen, Pauls, Scharf, Schroeder, Stewart, Ms. Yu, Gerber, Osecki, Gollagher, and Messrs. Wolf, Haddad, and Kirby are with Massachusetts General Hospital, Boston. Dr. Stewart is also with the University of British Columbia, Vancouver. Dr. McGrath is also with American University, Washington, DC. Dr. Scharf is also with Brigham and Women’s Hospital, Boston. Drs. D’Oudshoorn, McGrath, Neale, Rettyscher, Scharf, and Ms. Yu are also with the Harvard-MIT Broad Institute, Boston. Drs. Marshall, Scherer, Barr, Richter, Arnold, Sandoz, Ms. Thiruvahindrapuram and Ms. Li are with the University of Toronto and the Hospital for Sick Children, Toronto. Drs. Sandoz and Barr are also with the Toronto Western Research Institute, University Health Network, Toronto. Dr. Kennedy is with the Centre for Addiction and Mental Health, Toronto. Drs. Davis, Evans, and Cox are with the University of Chicago. Drs. Vallada, Miguel, and Brentani and Ms. Cappi are with the University of São Paulo Medical School. Dr. Belotti is with the Universita’ Vita-Salute San Raffaele, Milan. Dr. Benaroch is with Hadassah-Hebrew University Medical Center, Jerusalem. Drs. Benzvenu, Cullen, Giordas, Samuels, Singer, Nestadt, Riddle, and Ms. Wang are with Johns Hopkins University School of Medicine, Baltimore. Dr. Black is with the University of Iowa College of Medicine, Iowa City. Dr. Bloch, Coric, Fernandez, Leckman, Pakias, Pittenger, and King are with the Yale University School of Medicine, New Haven, CT. Drs. Bruin and Budman are with North Shore-Long Island Jewish Medical Center, New Hyde Park, NY. Dr. Budman is also with Hofstra University School of Medicine, Hempstead, NY. Dr. Bruin is also with New York University Medical Center, New York, NY. Ms. Camarena is with the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico. Dr. Calif is with Utrecht University and VU Medical Center, Amsterdam. Dr. Smit is with VU University Amsterdam. Dr. Cavallini is with the Capedele San Raffaele, Milan. Drs. Chouinard and Dion are with the University of Montreal. Drs. Delorme and Leboyer are with the Robert Debre University Hospital, Paris and the French National Science Foundation, Cretel, France. Dr. Delorme is also with Institut Pasteur, Paris. Dr. Leboyer is also with Institut Mondor de Recherche Biomédicale, Cretel, France. Dr. Denys and the Netherlands Institute for Neuroscience, Amsterdam. Drs. Demeny and Deeks are with the Academic Medical Center, Amsterdam. Drs. Rosario, Hourie, and Sampaio are with the Federal University of São Paulo. Dr. Sampaio is also with Universidade Federal da Bahia, Salvador, Bahia, Brazil. Dr. Espen is with the University of New South Wales, Australia. Dr. Falkai is with the University of Munich. Drs. Herrera and Ms. Garrido are with the Hospital Nacional de Niños, San Jose, Costa Rica. Ms. Garrido is also with Clinica Herrera Amighetti, Avenida Escazú, San José, Costa Rica. Dr. Grabe is with the University Medicine Greifswald, Greifswald, Germany. Dr. Greenberg is with Brown Medical School, Providence, RI. Drs. Grossman and Dr. R. Althoff are with Shlaxa Zedek Medical Center, Jerusalem. Drs. Grünblatt and Walitza are with the University of Zurich. Dr. Walitza is also with the University of Würzburg. Drs. Heiman and Tischfield are with Rutgers University, Piscataway Township, NJ. Dr. Jankovic is with Baylor College of Medicine, Houston. Dr. Kurlan is with the Atlantic Neuroscience Institute, Summit, NJ. Drs. Lanzagorta and Nicolini are with the Carracci Medical Group, Mexico City. Dr. Lebett is with University of California, Irvine. Drs. McCracken, Picciotti, Nuñez, and Freimer are with the University of California, Los Angeles (UCLA) School of Medicine. Dr. Freimer is also with Semel Institute for Neuroscience and Human Behavior, UCLA. Dr. Mcmahon is with the University of Utah, Salt Lake City. Drs. Murphy, Wendland and Shugart are with the National Institute of Mental Health (NIMH) Intramural Research Program, Bethesda, MD. Dr. Naarden is with Medical City Dallas Hospital, Dr. Ms. Pato, C. Pato, Knowless, and Wang are with the Zilkha Neurogenetic Institute, Los Angeles. Dr. Richter is with Sunnybrook Health Sciences Centre, Toronto. Drs. Robertson and Ruiz-Linares are with University College London. Dr. Rosenberg is with Wayne State University and Detroit Medical Center, Detroit. Dr. Rouleau is with the Montreal Neurological Institute. Dr. Rühe is with the University of Cologne, Germany. Dr. Smit is with VU Medical Center, Amsterdam. Dr. Stein is with the University of Cape Town, South Africa. Dr. Veenstra-VanderWeele is with Vanderbilt University, Nashville, TN. Dr. Costra is with Erasmus Medical Center Rotterdam, the Netherlands. Dr. Heutink is with the German Center for Neurodegenerative Diseases, Bonn and VU Medical Center Amsterdam. Dr. Posthumus is with VU Amsterdam and Erasmus University Medical Center, Rotterdam. Dr. Hanna is with the University of Michigan, Ann Arbor, MI. Dr. Cook is with the University of Illinois at Chicago.

This work was supported by grants from the David Judah Fund, the Tourette Syndrome Association, the International OCD Foundation, and National Institutes of Health (U01NS040024 [D.L.P.]/NIMH/NSA, and N01-NS-979487, and N01-NS-973250 [D.L.P.]; K03MH053057 [J.M.S.]; T32MH016293 [J.M.S.]; T32NS073484 and T32NS062691 [N.B.F.]; K20MH10165 and R01MH32376 [G.L.H.]; R01MH82293 [G.A.H./R.A.K./J.A.T.]. Support also came from American Recovery and Reinvestment Act (ARRA) awards NS04002407S1 and NS16548-2951 (D.L.P.). This work was also supported by grants from the New Jersey Center for Tourette Syndrome and Associated Disorders, the German Research Foundation (Pa 244/1-6; DFG), the Ontario Mental Health Foundation (M.A.R. and J.L.K.), and T32MH018268 (J.F.L.). Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative (GEI, U01 HG004422). SAGE is 1 of the genome-wide association studies funded as part of the Genome Environment Association Studies (GEEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GEEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information for collection of data, and the Department of Biostatistics was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract ‘High
throughput genotyping for studying the genetic contributions to human disease (HHSN2612007282093). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cpgb/study.cgi?study_id=phs000092.v.1 through dbGaP accession number phs000092.v1. p. None of the funding agencies for this project had any influence on the design or conduct of the study, the management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

Disclosure: Dr. O’Dushaine has received funding from the Stanley Center for Psychiatric Research. Dr. Black has received a research grant from AstraZeneca and has received royalties from American Psychiatric Publishing, UpToDate, and Oxford University Press. Dr. Bloch has received grant or research support from the National Institutes of Health (NIH) K23 Award, the Schizophrenia and Depression, the Renbrandt Foundation, and the American Academy of Child and Adolescent Psychiatry Research Initiative Junior Investigator Award. Dr. Budman is currently receiving funding for Tourette syndrome clinical trials from Otsuka Pharmaceutical and has received research funding in the past year from Piyaphon Pharmaceuticals. She is also a speaker for the TSA-CDC partnership and was on the National Medical Advisory Board for TSA in the past year. Dr. Cath has received speaker’s honoraria from Pfizer pharmaceuticals and a research grant from the TSA foundation. Dr. Denys is a member of the advisory board of Lundbeck and has received occasional consultant fees from Medtronic for educational purposes. Dr. Rosario has received a grant from CNPq (Brazilian National Council) and has received research grants and/or consultancy honoraria from Novartis and Shire. Dr. Hernandez has received research funding from NIH (K08 MH099404-01), the Tourette Syndrome Foundation, and Shire. Dr. Geller has received research support from NIH and teaching honorarium from the American Academy of Child and Adolescent Psychiatry. Dr. Graber has received research grants from the German Research Foundation and the Federal Ministry of Education and Research Germany. He has also received speakers’ honoraria from Bristol-Myers Squibb, Eli Lilly and Co., and Servier, and travel funds from Eli Lilly and Co., Astra-Zeneca, and Servier. Dr. Greenberg has received research funding from F. Hoffmann-La Roche Pharmaceuticals, Ltd. Dr. Kennedy has received honoraria from Roche, Eli Lilly and Co., and Novartis. Dr. King has received support from NIH and Grills’ ICD. Dr. Leckman has received grant or research support from the National Institute of Mental Health (NIMH), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), TSA, CROSFO (formerly Tolerics Biotherapeutics), and the King’s College Generation Foundation. He has served on the speakers’ bureau of TSA. He has received royalties from John Wiley and Sons, McGraw Hill, and Oxford University Press. He has received donations to clinical and research programs by the Associates of the Yale Child Study Center. Dr. Macciardi has received payments and travel refunds from Pharma Company TEVA for a couple of meetings in 2012. Dr. McCracken has received speaker honoraria from the TSA and research grants from Otsuka, Roche, Seaside Therapeutics, NICHD, and NIMH. He has served as a consultant to Roche. Dr. Pienniti has received grant or research support from NIMH, Pfizer Pharmaceuticals through the Duke Clinical Research Institute CAPTN Network, and TSA. He has served as a consultant to the Coleman Research Group and NIMH. He has served on the speakers’ bureau of TSA and the International Obsessive Compulsive Disorder Foundation. He has received book royalties from Guilford Press and Oxford University Press. He is a coauthor of the Child OCD Impact Scale-Revised (COIS-R), the Child Anxiety Impact Scale (CAIS), the Parent Tic Questionnaire (PTQ), and the Premontory Urge for Tics Scale (PUTS) assessment tools, all of which are in the public domain, therefore no royalties are received. He has received financial support from the Fulbright Family Foundation to develop a computerized child OCD treatment program. Dr. Pitterman has received honoraria for consulting from F. Hoffmann-La Roche Pharmaceuticals, Ltd. Dr. Richter has received honoraria from Lundbeck and has received research funding from Great-West Life Assurance Company of Canada and Eli Lilly Canada Ltd. Dr. Robertson has received grants from Tourette’s Action UK, TSA-USA. She has received honoraria from Janssen-Cilag, and book royalties from Wiley-Blackwell, David Fulton/Granada/Taylor Francis, Oxford University Press, and Jessica Kingsley Publishers. She is a patron of Tourette’s Action UK, sit on the medical advisory boards of the Italian Tourette Syndrome Association and the Tourette Syndrome Foundation of Canada, and is a Honorary Life President of ESSTS (European Society for the Study of Tourette’s Syndrome). Dr. Rosenberg has received consulting fees from Shire and research support from Children’s Hospital of Michigan Foundation and NIH. Dr. Sandor has received honoraria and research support from GlaxoSmithKline, Astra, Solvay, Otsuka, Piyaphon, TSA, Tourette Syndrome Foundation of Canada, and NIH. Dr. Stein has received research funding from Novartis, Roche, Seaside Therapeutics, Forest, Sunovion, and Symadix. Dr. Valitza has received lecture honoraria from Janssen Cilag, AstraZeneca, and Eli Lilly and Co. She has received research support from the Swiss National Science Foundation [SNF], Deutsche Forschungsgemeinschaft, EU FP7, and HSM Hochschulsieinte Medizinin of the Kanton, Zurich, Switzerland. Dr. Wendland is a part-time employee of F. Hoffmann-La Roche and a current employee of Pfizer. Dr. Nicolin has received grant/research support from Servier, Transcept, and Pherin. He has served as a consultant or on advisory boards for Servier, Transcept, Sanofi, and MSD. He has also served on speakers’ bureaus for MSD. Dr. Scherer has received funding from the government of Ontario. Dr. Arnold has received an unrestricted research grant from DNA Genotek. Dr. Stewart has received research support from the International OCD Foundation, the Anxiety Disorder Association of America, a Harvard Scholar Award, the Canadian Institutes of Health Research, the University of British Columbia, the Child and Family Research Institute, the British Columbia Mental Health and Addictions Research Institute, and the Michael Smith Foundation for Health Research. Dr. Mathews has received speaker honoraria and a research grant from the TSA and a research grant from the International OCD Foundation. Dr. Knowles has received research support from NIH, the International OCD Foundation, and Delia Martin Foundation, and speaker’s honoraria from Illumina, Inc. Dr. Cook has served as a consultant for and has had a research contract with Seaside Therapeutics. Dr. K. Wang is cofounder and shareholder of Tute Genomics, a bioinformatics consulting company. Dr. Schaif has received research support, honoraria, and travel support from TSA. He is also a member of the TSA Scientific Advisory Board. Ms. Yu has received research support from TSA and NIH. Ms. Fagerness was employed by Genomind: Drs. McGrath, Marshall, Davis, Schroeder, Illman, Barr, Bellodi, Banerchak, Bienvenu, Buin, Cavallini, Chouard, Coric, Cullen, Delorme, Derks, Dion, Eappen, Evans, Farka, Gidas, Gross-Tsur, Giurlaht, Heiman, Hemmings, Herrera, Housie, Jankovic, Johnson, Johnson, Lochner, Lowe, Lyon, Maier, McMahon, Murphy, Naarden, Neal, Nurni, Pakalts, M. Patco, Pato, Polak, Reus, Riddle, Rouleau, Ruhrmann, Sampaio, Samuels, Singer, Smit, Tischfield, Vallada, Stupart, Miguel, Olatsa, Moessner, Wagner, Ruiz-Linares, Heinitz, Nestadt, Freimer, Peyrset, Posthumus, Jenke, Cox, Hanna, Brennans, Pauls, and Mr. Thiruvilamkairum. Mr. L, Ms. Cappi, Ms. Gerber, Mr. Wolf, Ms. Olesiak, Mr. Kirby, Ms. Haddad, Ms. Gallagher, Ms. Camarena, Ms. Garrido, Mr. Leniritz, Ms. Sheppard, and Ms. Y. Wang report no biomedical financial interests or potential conflicts of interest.

The authors thank the families, patients, and control volunteers who participated in this research. The authors would like to acknowledge additional members of the Tourette Syndrome Association International Consortium for Genetics (TSAICG) and the International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDFGC), including Denise A. Chavira, PhD, Karin Egberts, MD, Eduardo Fournier, MS, Simon L. Girard, MSc, Jubel Morgan, RN, Tobias Renner, MD, Rowana Romero, MD, John Walkup, MD, and Herman G. Weinsten, PhD (deceased), for their contributions to this research.

Correspondence to Jeremiah Schaie, MD, PhD, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114; email: jcschaie@partners.org 08908567/36.00/6/2014 American Academy of Child and Adolescent Psychiatry

http://dx.doi.org/10.1016/j.jaac.2014.04.022
REFERENCES


